Llwytho...

Molecular Monitoring in Chronic Myeloid Leukemia: Response to Tyrosine Kinase Inhibitors and Prognostic Implications

The majority of patients with chronic-phase (CP) chronic myeloid leukemia (CML) who are treated with Bcr-Abl tyrosine kinase inhibitors such as imatinib and dasatinib achieve cytogenetic disease remission (ie, Philadelphia chromosome-positive cells undetectable by cytogenetic evaluation). However, m...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Cancer
Prif Awduron: Jabbour, Elias, Cortes, Jorge E., Kantarjian, Hagop M.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2008
Pynciau:
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5141579/
https://ncbi.nlm.nih.gov/pubmed/18348294
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.23427
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!